Busulfan, fludarabine, and alemtuzumab conditioning and unrelated cord blood transplantation in children with sickle cell disease

Biol Blood Marrow Transplant. 2013 Apr;19(4):676-7. doi: 10.1016/j.bbmt.2013.02.002. Epub 2013 Feb 9.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alemtuzumab
  • Anemia, Sickle Cell / immunology
  • Anemia, Sickle Cell / pathology
  • Anemia, Sickle Cell / therapy*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Busulfan / therapeutic use*
  • Child
  • Child, Preschool
  • Cord Blood Stem Cell Transplantation*
  • Female
  • Graft Rejection
  • Graft Survival / drug effects
  • Humans
  • Infant
  • Male
  • Myeloablative Agonists / therapeutic use*
  • Transplantation Conditioning*
  • Unrelated Donors
  • Vidarabine / analogs & derivatives*
  • Vidarabine / therapeutic use

Substances

  • Antibodies, Monoclonal, Humanized
  • Myeloablative Agonists
  • Alemtuzumab
  • Vidarabine
  • Busulfan
  • fludarabine